ERBB2 and breast carcinoma: Overall survival and disease-free survival were both significantly improved in women with early and locally advanced HER2+ breast cancers treated with chemotherapy first followed by Trastuzumab, compared with women treated only with chemotherapy, while also increasing cardiac toxicity.